Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. (Vor Bio) (Nasdaq: VOR) is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a dual BAFF/APRIL fusion protein. The VOR news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Vor Bio’s telitacicept program and corporate strategy evolve over time.
According to recent announcements, Vor Bio’s news flow centers on late-stage clinical data for telitacicept in B‑cell–mediated autoimmune diseases, including generalized myasthenia gravis, Sjögren’s disease, systemic lupus erythematosus, and IgA nephropathy. The company and its collaborator RemeGen Co., Ltd. have reported Phase 3 results from studies conducted in China, including data presented at major medical meetings and in peer‑reviewed publications. These updates highlight efficacy endpoints, durability of response, and safety findings for telitacicept across multiple indications.
Investors following VOR news can also track capital markets activity, such as underwritten public offerings, private placements with institutional healthcare investors, and at‑the‑market equity sales programs disclosed in company press releases and Form 8‑K filings. Additional news items cover leadership and governance changes, including appointments to the Board of Directors and executive team roles like Chief Medical Officer, Chief Development Officer, and Chief Commercial Officer, which Vor Bio links to its late-stage development and potential commercialization plans.
Vor Bio’s participation in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference and other sector-focused meetings, is another recurring news theme. Visitors to this page can review updates on upcoming presentations, webcasts, and corporate slide decks referenced in SEC filings. For anyone monitoring VOR, the news feed offers a centralized view of clinical milestones, financing decisions, and strategic developments related to telitacicept and Vor Bio’s broader autoimmune disease focus.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for Wednesday, February 12th at 12:00pm ET and conduct virtual one-on-one meetings with investors.
The event will be held virtually, and interested parties can access both the live webcast and archived replay of the fireside chat through the investors section of www.vorbio.com.
Vor Bio (Nasdaq: VOR) has appointed Mr. Erez Kalir to its Board of Directors, creating a new board seat following a recent private investment in public equity (PIPE) financing led by Reid Hoffman. Kalir will serve as director designee of Hoffman's investment fund, Reprogrammed Interchange,
Currently Managing Member of Martial Eagle Fund and Venture Partner at FJ Labs, Kalir brings extensive experience in biotech investments and entrepreneurship. He authors the Biotech Frontiers newsletter for Porter & Co. and previously worked at Tiger Management with Julian H. Robertson, advising on biotech and healthcare investments.
Kalir's appointment strengthens Vor Bio's leadership as the company advances its trem-cel platform and VCAR33 through regulatory approval. His background includes an MSc in cell biology from Oxford as a Rhodes Scholar, a JD from Yale Law School, and an A.B. from Stanford University.
Vor Bio (Nasdaq: VOR) has secured a $55.6 million private placement investment (PIPE), led by new investor Reid Hoffman with participation from existing stockholder RA Capital Management. The company will issue approximately 55.9 million shares of common stock and warrants to purchase about 69.8 million shares at $0.99425 per share and accompanying warrants. The warrants, exercisable through 2031 at $0.838 per share, could generate additional proceeds of up to $58.5 million.
The company plans to announce updated clinical data from two trials in 2025: the Phase 1/2 VBP301 trial of VCAR33ALLO in H1 and the Phase 1/2a VBP101 trial of trem-cel with Mylotarg in H2. Both Hoffman and RA Capital Management will receive one board seat and one board observer seat. The funding extends Vor Bio's cash runway through the release of these trial updates.
Vor Bio has released updated clinical data from its Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The study showed promising results with 25 patients treated with trem-cel, of which 15 received Mylotarg. Key findings include improved relapse-free survival, successful blood system shielding, and reliable engraftment with 100% of patients achieving primary neutrophil engraftment (median 9.5 days).
The company received supportive feedback from the FDA regarding their registrational trial design, with agreement on study population, control arm, primary endpoint, stratification factors, and statistical design. The FDA acknowledged trem-cel's neutrophil and platelet engraftment capabilities and its safety profile comparable to unedited CD34+ grafts.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat scheduled for Monday, November 18, 2024, at 2:25 pm ET in New York, NY. Additionally, Vor Bio will host one-on-one investor meetings during the conference. Interested parties can access both live webcast and archived replay of the fireside chat through the investors section of the company's website at www.vorbio.com.
Vor Bio reported Q3 2024 financial results and corporate updates. The company's net loss decreased to $27.6M from $33.2M year-over-year. Cash position stands at $62.8M, projected to fund operations into H2 2025. R&D expenses decreased to $21.8M from $27.6M, while G&A expenses reduced to $6.7M from $7.7M. Clinical progress includes 25 patients dosed with trem-cel and 6 patients receiving Mylotarg at 2 mg/m2. The company appointed Han Choi as CFO and plans to present updated clinical data at the upcoming ASH annual meeting.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has appointed Han Choi, M.D., LL.M., as its new Chief Financial Officer. Dr. Choi brings over 25 years of experience in investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. He will report directly to the company's President and CEO, Dr. Robert Ang.
Dr. Choi's expertise includes structuring corporate partnerships, managing complex transactions, and capital markets strategy. Prior to joining Vor Bio, he was a Principal at Oracle Investment Management, Inc., a healthcare-focused hedge fund. He has also held positions at Pharmacia and Bristol-Myers Squibb Company. Dr. Choi received his M.D. from Mount Sinai School of Medicine and law degrees from Oxford University and Harvard Law School.
PureTech Health's Founded Entity, Vor Bio (Nasdaq: VOR), announced new clinical data from its ongoing Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The data showed:
- Reliable engraftment with 100% primary neutrophil engraftment
- High CD33 editing efficiency (median 89%)
- Shielding of the blood system across multiple Mylotarg doses
- Broadened therapeutic index for Mylotarg
- Early evidence of patient benefit in relapse-free survival
Vor Bio plans to discuss a pivotal trial design with the FDA by year-end. The company also reported progress with VCAR33ALLO and introduced a new preclinical asset, VADC45, targeting CD45 for various blood disorders.
Vor Bio (Nasdaq: VOR) has announced promising clinical data from its Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The data showed reliable engraftment, shielding from Mylotarg toxicity, and early evidence of patient benefit. Key findings include:
- 100% primary neutrophil engraftment (median 9 days)
- High CD33 editing efficiency (median 89%)
- Maintained blood cell counts across multiple Mylotarg doses
- Broadened therapeutic index for Mylotarg
Vor Bio plans to discuss a pivotal trial design with the FDA by year-end. The company also reported progress with VCAR33ALLO and introduced a new preclinical asset, VADC45, targeting CD45 for various applications in oncology, gene therapy, and autoimmune disorders.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in three upcoming investor conferences in New York, NY. The events include:
1. Morgan Stanley 22nd Annual Global Healthcare Conference - 1x1 Investor Meetings on Friday, September 6, 2024
2. Baird 2024 Global Healthcare Conference - Fireside Chat on Wednesday, September 11, 2024, at 7:55am ET
3. Chardan's 8th Annual Genetic Medicines Conference - Fireside Chat on Monday, September 30, 2024, at 4:30pm ET
These conferences provide Vor Bio with opportunities to engage with investors and showcase their latest developments in cell and genome engineering.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
